148766-15-8

Basic information

• Product Name: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-
• CAS NO: 148766-15-8
• Molecular Formula: C13H13NO3
• Molecular Weight: 231.251
• Mol File: 148766-15-8.mol

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-(148766-15-8)
• EPA Substance Registry System: 2-Oxazolidinone, 3-[(2E)-1-oxo-2-butenyl]-4-phenyl-, (4R)-(148766-15-8)

Safety Data

• Hazardous Substances Data: 148766-15-8(Hazardous Substances Data)

Upstream product

• 623-68-7 trans-crotonic anhydride 
• 99395-88-7 (S)-4-phenyl-2-oxazolidinone 
• 591-97-9 1-chloro-2-butene 
• 623-68-7 crotonic anhydride 
• 107-93-7 (E)-but-2-enoic acid 
• 90319-52-1 (4R)-phenyl-2-oxazolidinone 
• 625-35-4 trans-chrotonyl chloride 
• 20989-17-7 (2S)-2-phenylglycinol 
• 2935-35-5 (S)-2-phenylglycine 

Downstream Products

• 146137-33-9 (4S)-4-phenyl-3-(3-phenylbutanoyl)oxazolidin-2-one 
• 148706-31-4 (S)-3-((2S,3S)-2-Bromo-3-phenyl-butyryl)-4-phenyl-oxazolidin-2-one 
• 148706-33-6 (S)-3-[(2S,3S)-2-Bromo-3-(2,6-dimethyl-phenyl)-butyryl]-4-phenyl-oxazolidin-2-one 
• 619328-34-6 (4S,2'S,3'S,5'S)-3-(7'-benzyloxy-2',3',5'-trimethylheptanoyl)-4-phenyloxazolidin-2-one 
• 1197007-12-7 (2'S,2R,3S,4S)-{[2-(4-bromophenyl)-3,4-dihydro-4-methyl-2-(4-nitrophenyl)-5-phenyl-2H-pyrrol-3-yl]-carbonyl}-2-oxo-4-phenyloxazolidine 
• 1197007-13-8 (2'S,2R,3S,4S)-{[3,4-dihydro-4-methyl-2-(4-nitrophenyl)-5-(furyl-2-yl)-2H-pyrrol-3-yl]-carbonyl}-2-oxo-4-phenyloxazolidine 
• 1197007-15-0 (2'S,2R,3S,4S)-{[3,4-dihydro-4-methyl-2-(4-nitrophenyl)-5-(thiophen-2-yl)-2H-pyrrol-3-yl]-carbonyl}-2-oxo-4-phenyloxazolidine 
• 1197007-16-1 (2'S,2R,3S,4S)-{[5-tert-butyl-3,4-dihydro-4-methyl-2-(4-nitrophenyl)-2H-pyrrol-3-yl]-carbonyl}-2-oxo-4-phenyloxazolidine 
• 1197006-69-1 (2'S,2R,3S,4S)-{[3,4-dihydro-4-methyl-2-(4-nitrophenyl)-5-phenyl-2H-pyrrol-3-yl]-carbonyl}-2-oxo-4-phenyloxazolidine 
• 1197007-17-2 (2'S,2R,3S,4S)-{[3,4-dihydro-4-methyl-2,5-diphenyl-2H-pyrrol-3-yl]-carbonyl}-2-oxo-4-phenyloxazolidine 
• 146137-34-0 (4S)-4-phenyl-3-<(3S)-3-phenylbutyryl>oxazolidin-2-one 

Relevant articles and documents

Antineoplastic agents. 599. Total synthesis of dolastatin 16

The first 23-step total synthesis of the cyclodepsipeptide dolastatin 16 (1) has been achieved. Synthesis of the dolaphenvaline and dolamethylleuine amino acid units using simplified methods improved the overall efficiency. The formation of the 25-membere

Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties ()

Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles. Epidemiological evidence correlates increased HDL and decreased LDL to coronary heart disease (CHD) risk reduction. This relationship is consistent with a clinical outcomes trial of a CETP inhibitor (anacetrapib) combined with standard of care (statin), which led to a 9% additional risk reduction compared to standard of care alone. We discuss here the discovery of MK-8262, a CETP inhibitor with the potential for being the best-in-class molecule. Novel in vitro and in vivo paradigms were integrated to drug discovery to guide optimization informed by a critical understanding of key clinical adverse effect profiles. We present preclinical and clinical evidence of MK-8262 safety and efficacy by means of HDL increase and LDL reduction as biomarkers for reduced CHD risk.

Intermediate for preparing halichondrin compound and preparation method thereof

The invention relates to an intermediate for preparing a halichondrin compound and a preparation method thereof. The invention particularly relates to an intermediate for preparing halichondrin, eribulin or analogues thereof, and a preparation method and application of the intermediate. The intermediate as well as the preparation method and application thereof are used for constructing C20-C26 structural fragments of the halichondrin compound. The initial raw materials of the synthesis route are cheap, easy to obtain, stable in source and reliable in quality; the structural characteristics ofreactants are fully utilized in the selection of a chiral center construction method, so that the synthesis efficiency is practically improved, and the difficulty and risk of product quality control are reduced; and the use of a high-toxicity and expensive organic tin catalyst is avoided, so that the cost and the environmental friendliness are remarkably improved.

SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN

The disclosure is directed to compounds of Formula I (I) Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

Nucleophilic halo-michael addition under lewis-base activation

A simple and general conjugate nucleophilic halogenation is presented. The THTO/halosilane combination has shown the ability to act as a nucleophilic halide source in the conjugate addition to a variety of Michael acceptors. In addition, a straightforward diastereoselective halogen installation using α,β-unsaturated acyloxazolidinones as platforms has been developed.

Visible light photocatalytic asymmetric synthesis of pyrrolo[1,2-: A] indoles via intermolecular [3+2] cycloaddition

The intermolecular diastereoselective and enantioselective synthesis of pyrrolo[1,2-a]indoles is developed through a [3+2] cycloaddition between silyl-indole derivatives and α,β-unsaturated N-acyl oxazolidinones by merging photocatalysis and Lewis acid catalysis.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

Palladium-Catalyzed Diastereoselective Synthesis of 3-Arylbutanoic Acid Derivatives

The first palladium-catalyzed diastereoselective conjugate addition of arylboronic acids to chiral imides is reported. The catalytic system employing 4-tert-butyloxazolidin-2-one as the chiral auxiliary in a mixed solvent system of MeOH/H2O (1:3) under an air atmosphere provides the optically active 3-arylbutanoic acid derivatives in excellent yields with high diastereoselectivity.

Dihydropyrazole GPR40 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.